PAIN AID ESF- (Acetaminopehn USP 250mg, Asprin USP 250mg Caffeine 65mg) coated, bulk OTC tablets ...

FDA Drug Recall #D-0327-2022 — Class II — November 29, 2021

Recall Summary

Recall Number D-0327-2022
Classification Class II — Moderate risk
Date Initiated November 29, 2021
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm ULTRAtab Laboratories, Inc.
Location Highland, NY
Product Type Drugs
Quantity 14 bulk lots (approximately 1,987,951 tablets each)

Product Description

PAIN AID ESF- (Acetaminopehn USP 250mg, Asprin USP 250mg Caffeine 65mg) coated, bulk OTC tablets packaged in corrugated boxes lined with 2 polyethylene bags 100 lb, ULTRAtab Laboratories, Inc. NDC# 62959-560-00, Product Code M560L

Reason for Recall

CGMP Deviations: failed stability results, inadequate laboratory investigations,

Distribution Pattern

Product was distributed to one customer who may have further distributed the product.

Lot / Code Information

Bulk Lots: 18K070, exp. date Nov-21; 19A046, exp. date Jan-22; 19C073, exp. date Mar-22; 19E014, exp. date May-22; 19G039, exp. date Jul-22; 19K002, exp. date Nov-22; 20A013, exp. date Jan-23; 20B050, exp. date Feb-23; 20C011, exp. date Mar-23; 20C049, exp. date Mar-23; 20F071, exp. date Jun-23; 20F072, exp. date Jun-23; 20G033, exp. date Jul-23; 20G041, exp. date Jul-23.

Other Recalls from ULTRAtab Laboratories, Inc.

Recall # Classification Product Date
D-0536-2022 Class II APAP 500 mg tablet (Acetaminophen 500 mg) Bulk ... Jan 26, 2022
D-0547-2022 Class II Migrenol Caplet (Acetaminophen 500 mg, Caffeine... Jan 26, 2022
D-0528-2022 Class II Coated APAP 325 mg Phenyl HCl 5 mg tablet (Acet... Jan 26, 2022
D-0541-2022 Class II Trial Antacid Tablet (Calcium Carbonate 420 mg)... Jan 26, 2022
D-0552-2022 Class II Legatrin (Acetaminophen 500 mg, Diphenhydramine... Jan 26, 2022

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.